In a surprise move, the US Food and Drug Administration (FDA) has now reversed its decision to deny the advancement of the biologics license application (BLA) for Moderna’s new flu shot candidate, mRNA-1010.
In last week’s shocking refusal-to-file letter (RTF), the FDA’s Center for Biologics Evaluation and Research (CBER)
Register for free to keep reading
To continue reading this article and unlock full access to GRIP, register now. You’ll enjoy free access to all content until our subscription service launches in early 2026.
- Unlimited access to industry insights
- Stay on top of key rules and regulatory changes with our Rules Navigator
- Ad-free experience with no distractions
- Regular podcasts from trusted external experts
- Fresh compliance and regulatory content every day